Jorge F Saucedo

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. ncbi Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
  2. doi Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd, WP 3010, Oklahoma City, OK 73104, USA
    Thromb Haemost 109:347-55. 2013
  3. doi Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome
    Jorge Felix Saucedo
    University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Prim Care Diabetes 6:167-77. 2012
  4. doi Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Boulevard, Oklahoma City, OK 73104, USA
    J Thromb Thrombolysis 30:200-9. 2010
  5. ncbi Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Am J Cardiol 95:1453-6. 2005
  6. doi Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Boulevard, Oklahoma City, OK 73190, USA
    Am J Cardiol 104:4C-8C. 2009
  7. ncbi Use of the early invasive approach in the management of acute coronary syndromes
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, PO Box 26901, Room WP3010, Oklahoma City, OK 73190, USA
    Curr Cardiol Rep 6:287-91. 2004
  8. doi Systematic review of effectiveness of oral sirolimus after bare-metal stenting of coronary arteries for prevention of in-stent restenosis
    Tarun W Dasari
    Cardiovascular Section, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma Electronic address
    Am J Cardiol 112:1322-7. 2013
  9. doi Endovascular treatment of mesenteric ischemia
    Beau M Hawkins
    Department of Internal Medicine, Section of Cardiovascular Disease, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
    Catheter Cardiovasc Interv 78:948-52. 2011
  10. doi Endovascular repair of traumatic aortic injury: a novel arena in interventional cardiology
    Jigar H Patel
    Department of Internal Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    J Interv Cardiol 26:77-83. 2013

Collaborators

Detail Information

Publications28

  1. ncbi Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
    ....
  2. doi Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd, WP 3010, Oklahoma City, OK 73104, USA
    Thromb Haemost 109:347-55. 2013
    ....
  3. doi Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome
    Jorge Felix Saucedo
    University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Prim Care Diabetes 6:167-77. 2012
    ..Similar clinical benefits are seen with ticagrelor versus clopidogrel in patients with and without diabetes. Evidence suggests that prasugrel/aspirin may provide particular advantages for patients with diabetes mellitus...
  4. doi Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Boulevard, Oklahoma City, OK 73104, USA
    J Thromb Thrombolysis 30:200-9. 2010
    ..Increased awareness of the factors contributing to risks and benefits associated with the available antiplatelet agents will help guide physicians in choosing optimal regimens for all patients...
  5. ncbi Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Am J Cardiol 95:1453-6. 2005
    ....
  6. doi Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Boulevard, Oklahoma City, OK 73190, USA
    Am J Cardiol 104:4C-8C. 2009
    ..A critical review of the 2007 guidelines in these areas and new clinical data with currently available and soon-to-be-approved antiplatelet agents are presented...
  7. ncbi Use of the early invasive approach in the management of acute coronary syndromes
    Jorge F Saucedo
    University of Oklahoma Health Sciences Center, PO Box 26901, Room WP3010, Oklahoma City, OK 73190, USA
    Curr Cardiol Rep 6:287-91. 2004
    ..Despite these recommendations, data from a large nationwide registry show that the majority of high-risk patients with NSTE ACS are not being managed with an early invasive strategy...
  8. doi Systematic review of effectiveness of oral sirolimus after bare-metal stenting of coronary arteries for prevention of in-stent restenosis
    Tarun W Dasari
    Cardiovascular Section, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma Electronic address
    Am J Cardiol 112:1322-7. 2013
    ..In addition, ISR rates were comparable to DES with the added benefit of cost saving. ..
  9. doi Endovascular treatment of mesenteric ischemia
    Beau M Hawkins
    Department of Internal Medicine, Section of Cardiovascular Disease, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
    Catheter Cardiovasc Interv 78:948-52. 2011
    ..Our goal was to describe a single-center's experience in managing acute and chronic mesenteric ischemia with endovascular therapies...
  10. doi Endovascular repair of traumatic aortic injury: a novel arena in interventional cardiology
    Jigar H Patel
    Department of Internal Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    J Interv Cardiol 26:77-83. 2013
    ..To assess the feasibility of endovascular repair of traumatic aortic injuries performed by interventional cardiologists in collaboration with cardiothoracic surgeons...
  11. doi Fluoroscopy vs. traditional guided femoral arterial access and the use of closure devices: a randomized controlled trial
    Mazen S Abu-Fadel
    Department of Internal Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK 73104, USA
    Catheter Cardiovasc Interv 74:533-9. 2009
    ....
  12. doi Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature
    Tarun W Dasari
    Department of Internal Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Catheter Cardiovasc Interv 77:962-9. 2011
    ..The benefit of drug eluting stents (DES) over bare metal stents (BMS) in the treatment of such lesions is debatable. We therefore sought to do a literature search to review the available evidence comparing DES to BMS...
  13. pmc Isolated right ventricular infarction after modified Cabrol operation
    Reji M Pappy
    Section of Cardiovascular Medicine, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Tex Heart Inst J 39:133-7. 2012
    ..We also discuss the impact of conservative and reperfusion strategies on prognosis and long-term outcomes in the setting of right ventricular infarction...
  14. doi Antiplatelet and anticoagulant therapies in acute coronary syndromes
    Elias B Hanna
    Cardiology Department, Oklahoma University, Oklahoma City, 73190, USA
    Cardiovasc Drugs Ther 24:61-70. 2010
    ..Combining multiple antiplatelet agents and an anticoagulant is the standard of care for ACS...
  15. doi In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    Faisal Latif
    University of Oklahoma, Oklahoma City, Oklahoma, USA
    JACC Cardiovasc Interv 2:37-45. 2009
    ..This study sought to evaluate ischemic and bleeding outcomes in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES)...
  16. doi Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes
    Lisa K Jennings
    Vascular Biology Center of Excellence, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Curr Opin Cardiol 23:302-8. 2008
    ..This review evaluates and interprets the role of oral antiplatelet agents, glycoprotein IIb-IIIa inhibitors, and bivalirudin in the context of current clinical evidence and practice...
  17. ncbi Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Am J Cardiol 90:585-90. 2002
    ..There is no evidence of a statistical interaction in the treatment effect of eptifibatide between patients with and without diabetes...
  18. ncbi Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention
    Ibrahim E Fahdi
    University of Arkansas School for Medical Sciences, Little Rock, Arkansas, USA
    Am J Cardiol 93:453-5. 2004
    ..The inhibition of platelet adhesion to fibrinogen-coated material by abciximab and eptifibatide was similar, indicating that the reduction in platelet count with abciximab is unrelated to inhibition of platelet function...
  19. ncbi Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study)
    Jorge F Saucedo
    University of Arkansas for Medical Sciences and Central Arkansas Veterans Health Care System, Little Rock, AR, USA
    Am J Cardiol 93:1279-82. 2004
    ....
  20. ncbi Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study
    Jorge F Saucedo
    University of Arkansas for Medical Sciences and Central Arkansas Veterans Health Care System, Little Rock, Arkansas, USA
    J Thromb Thrombolysis 18:67-74. 2004
    ..As previous studies found, a 12 hr abciximab infusion had <80% PAI, particularly at 6 and 12 hr. These studies did not evaluate PAI with a longer, 24-hour infusion as used in GUSTO IV ACS...
  21. ncbi Racial and ethnic differences in the treatment and outcome of cardiogenic shock following acute myocardial infarction
    Sebastian T Palmeri
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Am J Cardiol 96:1042-9. 2005
    ..Therefore, early revascularization should be strongly considered for all patients, independent of race/ethnicity, who develop cardiogenic shock after acute myocardial infarction...
  22. ncbi Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early imp
    Mauricio G Cohen
    Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7075, USA
    Am Heart J 152:110-7. 2006
    ..Data regarding the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) in Hispanic patients, the largest and fastest-growing minority in the United States, are scarce...
  23. ncbi Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:641-7. 2006
    ..We sought to determine the prevalence, predictors, and outcomes of patients with NSTEMI and insignificant CAD...
  24. ncbi Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology and the Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina USA
    Am J Cardiol 98:1172-6. 2006
    ..In conclusion, despite the overall increase in the use of early catheterization, the gap between the use of an early invasive strategy in the highest and lowest risk patients remains large and tends to increase over time...
  25. ncbi Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Regist
    Jason W Ryan
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 112:3049-57. 2005
    ....
  26. ncbi "No-option" patients: a nightmare today, a future with hope
    Thomas A Hennebry
    J Interv Cardiol 17:93-4. 2004
  27. ncbi Five-year clinical and angiographic follow-up after intracoronary iridium-192 radiation therapy
    Jose A Condado
    Department of Cardiology Hospital Miguel Perez Carreno, Centro Medico, Caracas, Venezuela
    Cardiovasc Radiat Med 3:74-81. 2002
    ..The outcome of these patients is presented and discussed...
  28. ncbi Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative)
    Prospero B Gogo
    University of Vermont College of Medicine, Burlington, Vermont, USA
    Am J Cardiol 99:1222-6. 2007
    ..Long-term implications of this shift remain uncertain, especially in patients with 3VD...